Company profile: Korro Bio
1.1 - Company Overview
Company description
- Provider of efficient, selective RNA editing solutions leveraging natural processes: OPERA, a platform using oligonucleotides for precise single-base edits to modulate protein function; KRRO-110, an oligonucleotide candidate for Alpha-1 Antitrypsin Deficiency via SERPINA1 RNA editing; and CHORDs, customized high-fidelity oligonucleotides for RNA deamination.
Products and services
- OPERA: An oligonucleotide-based platform that makes precise, single-base RNA edits to modulate protein function, leveraging natural processes common to multicellular organisms
- CHORDs: Custom-engineered oligonucleotides for RNA deamination, achieving high-fidelity editing with enhanced in vivo potency and durability for improved RNA editing performance
- KRRO-110: A sequence-specific oligonucleotide product candidate that edits SERPINA1 RNA, engineered for the treatment of Alpha-1 Antitrypsin Deficiency (AATD) through precise RNA editing.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Korro Bio
Biotheranostics
HQ: United States
Website
- Description: Provider of commercial-stage molecular diagnostics, delivering diagnostic, prognostic, and predictive tests that support physicians in treating cancer, including Breast Cancer Index, a genomic test predicting benefit of extended endocrine therapy in HR+, early-stage breast cancer, and CancerTYPE ID, a gene expression assay identifying tumor type/subtype in metastatic cancer with unknown or unclear diagnoses.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Biotheranostics company profile →
Strata Oncology
HQ: United States
Website
- Description: Provider of precision oncology solutions, including Strata Select, a DNA/RNA-based molecular profiling test guiding immunotherapy and other treatment selection for advanced cancer; the Immunotherapy Response Score predicting benefit of anti-PD-1/PD-L1 monotherapy; and clinical trials such as Strata PATH and Strata Trial enabling biomarker-guided evaluation and access to approved and investigational therapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Strata Oncology company profile →
Enigma Diagnostics
HQ: United Kingdom
Website
- Description: Provider of fully automated molecular testing devices for clinics, plus biological products including protein standards (Purified GFP, Plasmodium falciparum, Canine Heartworm Antigen for veterinary diagnostics), the IFI27 gene biomarker to distinguish influenza from bacterial infections, and the Adapter Chimeric Antigen Receptor preclinical NK-92 cell strategy targeting tumor cells in bone metastases.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Enigma Diagnostics company profile →
Cepheid
HQ: United States
Website
- Description: Provider of accurate, easy-to-use molecular diagnostic systems and tests that automate complex procedures for institutions of any size. Offerings include the GeneXpert System and single-use Xpert cartridges for nucleic acid extraction, amplification, and detection, plus Xpert Xpress PCR tests for Strep A, SARS-CoV-2, CoV-2/Flu/RSV, and Flu A/B.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Cepheid company profile →
Combinati
HQ: United States
Website
- Description: Provider of next-generation PCR technology for laboratories, enabling doctors and researchers to detect and track critical biomarkers.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Combinati company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Korro Bio
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Korro Bio
2.2 - Growth funds investing in similar companies to Korro Bio
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Korro Bio
4.2 - Public trading comparable groups for Korro Bio
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →